Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OTC | P00480 | 1/20 | 0.63 |
| ▸ | GSR | P00390 | 2/20 | 0.47 |
| ▸ | DDAH1 | O94760 | 3/20 | 0.47 |
| ▸ | NOD1 | Q9Y239 | 2/20 | 0.46 |
| ▸ | ARG2 | P78540 | 4/20 | 0.43 |
| ▸ | ARG1 | P05089 | 3/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.42 |
| ▸ | NOS2 | P35228 | 2/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.42 |
| ▸ | APEX1 | P27695 | 1/20 | 0.42 |
| ▸ | GRM8 | O00222 | 1/20 | 0.41 |
| ▸ | GRM6 | O15303 | 1/20 | 0.41 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.41 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.41 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.41 |
| ▸ | GRM5 | P41594 | 1/20 | 0.41 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5548101 | 1.00 | OTC (0.63) | OTCGSRDDAH1NOD1ARG2 | |
| SCHEMBL450798 | 0.95 | OTC (0.57) | OTCGSRDDAH1NOD1ARG2 | |
| SCHEMBL7826522 | 0.95 | OTC (0.57) | OTCGSRDDAH1NOD1ARG2 | |
| SCHEMBL25186309 | 0.83 | OTC (0.65) | OTCGSRDDAH1NOD1ARG2 | |
| SCHEMBL13043221 | 0.83 | OTC (0.65) | OTCGSRDDAH1NOD1ARG2 | |
| SCHEMBL25186310 | 0.83 | OTC (0.65) | OTCGSRDDAH1NOD1ARG2 | |
| SCHEMBL2237070 | 0.81 | OTC (0.63) | OTCGSRDDAH1NOD1ARG2 | |
| SCHEMBL2237074 | 0.81 | OTC (0.63) | OTCGSRDDAH1NOD1ARG2 | |
| SCHEMBL22689763 | 0.81 | OTC (0.54) | OTCGSRDDAH1NOD1ARG2 | |
| SCHEMBL2236948 | 0.80 | OTC (0.61) | OTCGSRDDAH1NOD1ARG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 112 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117521484-A | Sea surface wind speed inversion method and equipment based on single left-hand circularly polarized antenna | 中国气象局气象探测中心 | 2024-02-06 | — | — | CN | claimed |
| EP-3696281-A1 | ARGINASE AS BIOMARKER AND DRUG TARGET FOR PCOS | Johann Wolfgang Goethe-Universität Frankfurt am Main (DE) | 2020-08-19 | — | — | EP | claimed |
| US-20150335663-A1 | Pharmaceutical Composition Having Synergistic Action Of Direct Catalase Inhibitors And Modulators Of NO Metabolism Or Of Extracellular Superoxide Anion Production Which Lead To Catalase Destruction | UNIVERSITAETSKLINIKUM FREIBURG (DE) | 2015-11-26 | — | — | US | claimed |
| EP-2863907-A1 | PHARMACEUTICAL COMPOSITION HAVING SYNERGISTIC ACTION OF DIRECT CATALASE INHIBITORS AND MODULATORS OF NO METABOLISM OR OF EXTRACELLULAR SUPEROXIDE ANION PRODUCTION WHICH LEAD TO CATALASE DESTRUCTION | Universitätsklinikum Freiburg (DE) | 2015-04-29 | — | — | EP | claimed |
| WO-2014001183-A1 | PHARMACEUTICAL COMPOSITION HAVING SYNERGISTIC ACTION OF DIRECT CATALASE INHIBITORS AND MODULATORS OF NO METABOLISM OR OF EXTRACELLULAR SUPEROXIDE ANION PRODUCTION WHICH LEAD TO CATALASE DESTRUCTION | Universitätsklinikum Freiburg (DE) | 2014-01-03 | — | — | WO | claimed |
| JP-4723476-B2 | — | — | 2011-07-13 | — | — | JP | claimed |
| EP-1863431-A1 | HAIR AND/OR EYELASH CARE COMPOSITION CONTAINING AMINEXIL IN COMBINATION WITH AN AGENT FOR PROMOTING THE NO PRODUCTION AND USES THEREOF | L'Oréal (FR) | 2007-12-12 | — | — | EP | claimed |
| EP-1596854-A4 | TREATMENT OF CONDITIONS ASSOCIATED WITH DECREASED NITRIC OXIDE BIOAVAILABILITY, INCLUDING ELEVATED ARGINASE CONDITIONS | CHILDRENS HOSP & RES CT OAK (US) | 2007-06-06 | — | — | EP | claimed |
| WO-2006097359-A1 | HAIR AND/OR EYELASH CARE COMPOSITION CONTAINING AMINEXIL IN COMBINATION WITH AN AGENT FOR PROMOTING THE NO PRODUCTION AND USES THEREOF | L'ORÉAL (FR) | 2006-09-21 | — | — | WO | claimed |
| JP-2006518387-A | — | — | 2006-08-10 | — | — | JP | claimed |
| EP-1596854-A2 | TREATMENT OF CONDITIONS ASSOCIATED WITH DECREASED NITRIC OXIDE BIOAVAILABILITY, INCLUDING ELEVATED ARGINASE CONDITIONS | Children's Hospital & Research Center at Oakland (US) | 2005-11-23 | — | — | EP | claimed |
| US-20050158401-A1 | Treatment and diagnosis of conditions associated with elevated arginase activity | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2005-07-21 | — | — | US | claimed |
| WO-2004073623-A9 | TREATMENT OF CONDITIONS ASSOCIATED WITH DECREASED NITRIC OXIDE BIOAVAILABILITY, INCLUDING ELEVATED ARGINASE CONDITIONS | CHILDRENS HOSP & RES CT OAK (US) | 2005-01-27 | — | — | WO | claimed |
| WO-2004073623-A2 | TREATMENT OF CONDITIONS ASSOCIATED WITH DECREASED NITRIC OXIDE BIOAVAILABILITY, INCLUDING ELEVATED ARGINASE CONDITIONS | CHILDREN'S HOSPITAL & RESEARCH CENTER AT OAKLAND (US) | 2004-09-02 | — | — | WO | claimed |
| US-12569445-B2 | Particles comprising a therapeutic or diagnostic agent and suspensions and methods of use thereof | HALOZYME HYPERCON, INC. (US) | 2026-03-10 | — | — | US | disclosed |
| US-12558323-B2 | Particle formation and morphology | ELEKTROFI, INC. (US) | 2026-02-24 | — | — | US | disclosed |
| US-20260007615-A1 | PARTICLES COMPRISING A THERAPEUTIC OR DIAGNOSTIC AGENT AND SUSPENSIONS AND METHODS OF USE THEREOF | ELEKTROFI INC (US) | 2026-01-08 | — | — | US | disclosed |
| WO-2004073623-A2 | TREATMENT OF CONDITIONS ASSOCIATED WITH DECREASED NITRIC OXIDE BIOAVAILABILITY, INCLUDING ELEVATED ARGINASE CONDITIONS | CHILDREN'S HOSPITAL & RESEARCH CENTER AT OAKLAND (US) | 2004-09-02 | — | — | WO | disclosed |
| EP-1091958-A1 | SALTS OF PAROXETINE | SMITHKLINE BEECHAM PLC (GB) | 2001-04-18 | — | — | EP | disclosed |
| WO-2000001692-A1 | SALTS OF PAROXETINE | SMITHKLINE BEECHAM PLC (GB) | 2000-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12569445-B2 | Particles comprising a therapeutic or diagnostic agent and suspensions and methods of use thereof | ALB, S100P, S100A8 | OTC 1834/4885GSR 4809/4885DDAH1 4844/4885 |
| US-12558323-B2 | Particle formation and morphology | CD63, EXOSC10, EPCAM | OTC 3506/4885GSR 4614/4885DDAH1 4713/4885 |
| US-20260007615-A1 | PARTICLES COMPRISING A THERAPEUTIC OR DIAGNOSTIC AGENT AND SUSPENSIONS AND METHODS OF USE THEREOF | FLNB, FLNA, FUS | OTC 2070/4885GSR 4117/4885DDAH1 4474/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.